BioCentury
ARTICLE | Company News

BioDelivery Sciences, Endo deal

December 30, 2016 9:10 PM UTC

Endo will terminate a 2012 deal granting it exclusive, worldwide rights to develop and commercialize Belbuca buprenorphine to treat chronic pain, effective Jan. 6. BioDelivery will regain all rights to the product. The companies said they will have no further financial obligations. Earlier last year, Endo launched Belbuca in the U.S. to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate. The product is buprenorphine formulated with the BEMA transmucosal delivery system.

As a result of the termination, Endo said it will reduce its U.S. Branded pain sales force by 375. Endo expects to save $90-$100 million in 2017. Endo will focus on developing its Xiaflex collagenase clostridium histolyticum. The injectable form of collagenase is approved in the U.S. to treat adults with Dupuytren's contracture with palpable cords and adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30° at the start of therapy (see BioCentury, Jan. 9, 2012 & Feb. 29, 2016)...